Ruolun Qiu

1.2k total citations · 1 hit paper
34 papers, 761 citations indexed

About

Ruolun Qiu is a scholar working on Physiology, Molecular Biology and Rheumatology. According to data from OpenAlex, Ruolun Qiu has authored 34 papers receiving a total of 761 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Physiology, 8 papers in Molecular Biology and 6 papers in Rheumatology. Recurrent topics in Ruolun Qiu's work include Statistical Methods in Clinical Trials (5 papers), GDF15 and Related Biomarkers (4 papers) and Pharmacogenetics and Drug Metabolism (4 papers). Ruolun Qiu is often cited by papers focused on Statistical Methods in Clinical Trials (5 papers), GDF15 and Related Biomarkers (4 papers) and Pharmacogenetics and Drug Metabolism (4 papers). Ruolun Qiu collaborates with scholars based in United States, United Kingdom and Belgium. Ruolun Qiu's co-authors include Brendon Binneman, Sheela Kolluri, Douglas E. Feltner, Kaori Ito, Aditi R. Saxena, Brian Corrigan, Klaus Romero, Diane Stephenson, Thomas F. Kalhorn and Elena Peeva and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and American Journal of Psychiatry.

In The Last Decade

Ruolun Qiu

34 papers receiving 733 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ponsegromab for the Treatment of Cancer Cachexia

2024 97 citations John D. Groarke, Jeffrey Crawford et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Ruolun Qiu

Since Specialization

Citations

This map shows the geographic impact of Ruolun Qiu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruolun Qiu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruolun Qiu more than expected).

Fields of papers citing papers by Ruolun Qiu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruolun Qiu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruolun Qiu. The network helps show where Ruolun Qiu may publish in the future.

Co-authorship network of co-authors of Ruolun Qiu

This figure shows the co-authorship network connecting the top 25 collaborators of Ruolun Qiu. A scholar is included among the top collaborators of Ruolun Qiu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruolun Qiu. Ruolun Qiu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC‐1 study design 2024 ·Journal of Cachexia Sarcopenia and Muscle ·John D. Groarke, Jeffrey Crawford, Susie M. Collins, Shannon L. Lubaczewski, Danna M. Breen, Magdalena Harrington, Ira Jacobs, Ruolun Qiu, James H. Revkin, Michelle I. Rossulek, Aditi R. Saxena	20
2	The Metabolism and Disposition of Brepocitinib in Humans and Characterization of the Formation Mechanism of an Aminopyridine Metabolite 2024 ·Drug Metabolism and Disposition ·Martin E. Dowty, Ruolun Qiu, Alyssa Dantonio, Mark Niosi, Angela C. Doran, (unknown), Stephen W. Wright, Gregory S. Walker, Raman Sharma	4
3	Employing zero-inflated beta distribution in an exposure-response analysis of TYK2/JAK1 inhibitor brepocitinib in patients with plaque psoriasis 2024 ·Journal of Pharmacokinetics and Pharmacodynamics ·Nikolaos Tsamandouras, Ruolun Qiu, (unknown), Kevin Sweeney, (unknown), Christopher Banfield, Timothy Nicholas	2
4	Ponsegromab for the Treatment of Cancer Cachexia breakdown → 2024 ·New England Journal of Medicine ·John D. Groarke, Jeffrey Crawford, Susie M. Collins, Shannon L. Lubaczewski, Eric Roeland, Tateaki Naito, Andrew Hendifar, Marie Fallon, Koichi Takayama, Timothy R. Asmis, Richard F. Dunne, F. Işık Karahanoğlu, Carrie A. Northcott, Magdalena Harrington, Michelle I. Rossulek, Ruolun Qiu, Aditi R. Saxena	97
5	Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial 2023 ·Arthritis & Rheumatology ·Philip J. Mease, Philip Helliwell, (unknown), (unknown), Andrew J.K. Östör, Elena Peeva, Michael S. Vincent, (unknown), Vanja Sikirica, Randall Winnette, Ruolun Qiu, Gang Li, Gang Feng, Jean S. Beebe, Roland Martinꝉ	36
6	Study of the ketohexokinase inhibitor PF‐06835919 as a clinical cytochrome P450 3A inducer: Integrated use of oral midazolam and liquid biopsy 2023 ·Clinical and Translational Science ·Ruolun Qiu, Kari R. Fonseca, Arthur Bergman, Jian Lin, David A. Tess, Lauren A. Newman, (unknown), Zivile Useckaite, Andrew Rowland, Manoli Vourvahis, David Rodrigues	1
7	A phase 1 study to investigate the absorption, distribution, metabolism and excretion of brepocitinib in healthy males using a ¹⁴C‐microdose approach 2023 ·British Journal of Clinical Pharmacology ·Ruolun Qiu, Raman Sharma, (unknown), (unknown), Yifan Zhou, (unknown), Christopher Banfield, Martin E. Dowty	2
8	A phase 2a, randomized, double‐blind, placebo‐controlled, three‐arm, parallel‐group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF ‐06835919 in patients with non‐alcoholic fatty liver disease and type 2 diabetes 2022 ·Diabetes Obesity and Metabolism ·Aditi R. Saxena, (unknown), Kaivan Khavandi, Ruolun Qiu, Mark Whitlock, William P. Esler, Albert M. Kim	22
9	TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial 2020 ·Journal of Investigative Dermatology ·Seth Forman, David M. Pariser, Yves Poulin, Michael S. Vincent, Steven A. Gilbert, Elizabeth Kieras, Ruolun Qiu, Dahong Yu, Jocelyne Papacharalambous, (unknown), Elena Peeva	77
10	Pharmacokinetic and Pharmacodynamic Effects of a γ‐Secretase Modulator, PF‐06648671, on CSF Amyloid‐β Peptides in Randomized Phase I Studies 2019 ·Clinical Pharmacology & Therapeutics ·Jae Eun Ahn, (unknown), (unknown), Terence Fullerton, Éva Hajós‐Korcsok, Ping He, (unknown), (unknown), (unknown), Jessica Mancuso, (unknown), Ruolun Qiu	24
11	Minimization of CYP2D6 Polymorphic Differences and Improved Bioavailability via Transdermal Administration: Latrepirdine Example 2016 ·Pharmaceutical Research ·Marci L. Chew, Joyce Mordenti, (unknown), (unknown), Ruolun Qiu, Juanzhi Fang, Yali Liang, Brian Corrigan	3
12	The future is now: Model‐based clinical trial design for Alzheimer's disease 2014 ·Clinical Pharmacology & Therapeutics ·Klaus Romero, Kaori Ito, (unknown), (unknown), Ruolun Qiu, Diane Stephenson, Richard C. Mohs, R L Lalonde, Vikram Sinha, (unknown), (unknown), Maria Isaac, Spiros Vamvakas, Robert Hemmings, Luca Pani, (unknown), Brian Corrigan, (unknown)	49
13	P3‐367: Model‐based analysis to support strategic decision‐making: A case study from the development of a 5HT6 antagonist for the treatment of Alzheimer's disease 2012 ·Alzheimer s & Dementia ·James A. Rogers, (unknown), Peter Lockwood, Y. Brault, (unknown), Kaori Ito, Klaus Romero, Ruolun Qiu, Brian Corrigan, William R. Gillespie, Marc R. Gastonguay	1
14	Combining patient-level and summary-level data for Alzheimer’s disease modeling and simulation: a beta regression meta-analysis 2012 ·Journal of Pharmacokinetics and Pharmacodynamics ·James A. Rogers, (unknown), William R. Gillespie, Kaori Ito, Klaus Romero, Ruolun Qiu, Diane Stephenson, Marc R. Gastonguay, Brian Corrigan	59
15	P1‐259: Aβ variability and effect of gamma secretase inhibition on cerebrospinal fluid levels of Aβ in healthy volunteers 2009 ·Alzheimer s & Dementia ·Holly Soares, (unknown), (unknown), Dane Liston, (unknown), Karen J. Coffman, Barbara Tate, Ruolun Qiu, Ellen Q. Wang, Xiaoxi Li, (unknown), Subhashis Banerjee, Stanford S. Jhee, Larry Ereshefsky, Terence Fullerton	8
16	Exposure-response Analysis for Spontaneously Reported Dizziness in Pregabalin-treated Patient With Generalized Anxiety Disorder 2008 ·Clinical Pharmacology & Therapeutics ·Kaori Ito, (unknown), (unknown), Ruolun Qiu, Boy Frame, Raymond Miller	22
17	A 6-Week Randomized, Placebo-Controlled Trial of CP-316,311 (a Selective CRH ₁ Antagonist) in the Treatment of Major Depression 2008 ·American Journal of Psychiatry ·Brendon Binneman, Douglas E. Feltner, Sheela Kolluri, (unknown), Ruolun Qiu, (unknown)	185
18	ABCC2-Mediated Biliary Transport of 4-Glutathionylcyclophosphamide and Its Contribution to Elimination of 4-Hydroxycyclophosphamide in Rat 2004 ·Journal of Pharmacology and Experimental Therapeutics ·Ruolun Qiu, Thomas F. Kalhorn, John T. Slattery	28
19	Diminishing the risk of nonrelapse mortality in hematopoietic stem cell transplantation: Prediction of exposure to the cyclophosphamide metabolite carboxyethylphosphoramide mustard 2004 ·Clinical Pharmacology & Therapeutics ·Ruolun Qiu, Yao Assita, P. Vicini, (unknown), Ami Batchelder, M Bouvier, Stewart T. Cole, (unknown)	21
20	Molecular cloning and expression of Galβ1,3GalNAc α2,3‐sialyltransferase from human fetal liver 1999 ·European Journal of Biochemistry ·Jie Shang, Ruolun Qiu, (unknown), (unknown), Rouli Zhou, Huiping Ding, (unknown), Shuzheng Zhang, Cheng Jin	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact